Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: Comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression

Maurizio Miglino, Nicoletta Colombo, Raffaella Grasso, Carlo Marani, Marino Clavio, Gian Matteo Pica, Filippo Ballerini, Chiara Ghiggi, Paola Minetto, Fabio Guolo, Angelo Michele Carella, Marco Gobbi

Research output: Contribution to journalArticle

Abstract

We compared the clinical value of minimal residual disease (MRD) monitoring by cytofluorimetric methods, Wilms tumor gene 1 (WT1) expression and the study of nucleophosmin gene (NPM) mutations in a series of 26 patients with NPM-mutated de novo acute myeloid leukemia (NPM-AML) who achieved complete hematological remission after conventional chemotherapy. The relapse risk was significantly lower only in patients achieving a NPM molecular complete response (NPM mol-CR) and confirmed NPM mol-CR (non-detectable NPM mutations in two consecutive marrow samples). The disease-free survival (DFS) of patients achieving a

Original languageEnglish
Pages (from-to)2214-2217
Number of pages4
JournalLeukemia and Lymphoma
Volume53
Issue number11
DOIs
Publication statusPublished - Nov 2012

    Fingerprint

Keywords

  • AML
  • MRD
  • NPM
  • WT1

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this